肺癌术后放疗的适应证与参数
可切除局部晚期非小细胞肺癌复发风险高,辅助铂类化疗为标准治疗,但术后放疗(PORT)作用长期存在争议。完全切除(R0)且无纵隔受累(pN0、pN1)者PORT结局更差;pN2者作用不明确。近期Lung ART与PORT-C两项随机试验显示IIIA-N2期患者PORT未改善无病生存,虽纵隔复发显著减少。
要点
- 不完全切除者基于强共识应提议PORT,尽管缺乏随机证据。
- 完全切除R0且pN0/pN1者,Meta分析显示PORT后结局更差。
- pN2 R0者Lung ART与PORT-C未显示无病生存获益,纵隔复发显著减少。
核心结论
- 不完全切除者基于强共识应提议PORT,尽管缺乏随机证据。
- 完全切除R0且pN0/pN1者Meta分析显示PORT后结局更差,pN2者作用较不明确且需进一步研究。
- Lung ART与PORT-C两项随机试验中IIIA-N2期患者PORT未获得无病生存优势,纵隔复发显著减少但生存无影响,可能与远处复发率高及额外心肺毒性风险有关。
研究设计与样本
- 本文为综述,汇总Meta分析、回顾性及非随机研究、随机试验亚组分析以及Lung ART和PORT-C两项随机试验的证据。
主要发现
- Meta分析显示完全切除R0且无纵隔受累(pN0和pN1)者PORT后结局更差。
- pN2 R0者中较新的回顾性及非随机研究和辅助化疗随机试验亚组分析提示PORT有生存获益。
- Lung ART和PORT-C两项随机试验评估适形PORT对比无PORT,IIIA-N2期患者未获得无病生存优势,尽管PORT显著减少纵隔复发。
- PORT对生存无影响,可能因远处复发率高及额外心肺毒性风险。
关键数值与推荐
- 不完全切除者:基于强共识应提议PORT,尽管缺乏随机证据。
- 完全切除R0且pN0和pN1者:Meta分析显示PORT后结局更差。
- pN2者:PORT作用较不明确,需进一步研究。
- Lung ART和PORT-C:IIIA-N2期患者PORT未获得无病生存优势,纵隔复发显著减少。
临床怎么用
- 不完全切除者基于强共识应提议PORT,尽管缺乏随机证据。
- 完全切除R0且pN0和pN1者,Meta分析显示PORT后结局更差。
- pN2者PORT作用较不明确,需进一步研究;Lung ART和PORT-C未显示IIIA-N2期患者无病生存优势。
局限性
- Meta分析纳入使用较旧放疗技术和按当今标准手术质量较差的试验,且患者选择未基于正电子发射断层扫描。
- Lung ART和PORT-C中PORT对生存无影响,可能因远处复发率高及额外心肺毒性风险。
- 需在未来研究中通过分析循环肿瘤DNA、基于检测术后微小(或分子)残留病来更好地识别疾病复发高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with locally advanced resected non-small-cell lung cancer present a high risk of relapse. Although adjuvant platinum-based chemotherapy has become the standard of care, the role of postoperative radiation therapy (PORT) has been controversial for years. In patients with incomplete resection, PORT should be proposed, on the basis of a strong consensus, despite the absence of randomized evidence. In patients with completely resected (R0) non-small-cell lung cancer, a meta-analysis showed poorer outcomes after PORT in the absence of mediastinal involvement (pN0 and pN1). In patients with pN2, the role of PORT was less clear and required further research. The meta-analysis included trials using older radiation techniques and poorer quality of surgery according to today's standards, and selection of patients was not positron emission tomography-based. Newer retrospective and nonrandomized studies and subgroup analyses of randomized trials evaluating adjuvant chemotherapy suggested a survival benefit of PORT in patients with pN2 R0. Two recent randomized trials (Lung ART and PORT-C) evaluating conformal PORT versus no PORT retrieved no disease-free survival advantage for stage IIIA-N2 patients, even if mediastinal relapse was significantly decreased with PORT. PORT had no effect on survival, possibly given the high rate of distant relapse and risk of additional cardiopulmonary toxicity. Ongoing and future analyses are planned in Lung ART to identify patients for whom PORT could be recommended. Incorporation of newer systemic treatments (immune checkpoint inhibitors or targeted therapy in oncogene-addicted patients) is underway in the neoadjuvant and/or adjuvant setting. Better identification of patients at a high risk of disease recurrence, with analysis of circulating tumor DNA, on the basis of the detection of postsurgical minimal (or molecular) residual disease is warranted in future studies.
引用
- Levy A, Mercier O, Le Péchoux C, et al. Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer. J Clin Oncol. 2022. PMID: 34985927. doi:10.1200/JCO.21.01774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。